About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 569 record(s)
Req # A 2023_0011
1. Any document or information concerning the granting of the “Politically-Exposed Persons” (“PEP”) status upon individuals in Canada or elsewhere. 2. The complete list of individuals upon which the PEP status has been granted over the past 15 years. 3. The list of individuals who are currently designated as PEPs. 4. The involvement of your organization or government institution in the granting, maintenance or communication of the PEP status conferred upon individuals 5. A complete list of organizations, government institutions and third parties that have access to or are informed of the PEP status.Organization: Canada Development Investment Corporation
February 2024
Req # A-2019-000270
Adverse Drug Reactions (ADRs). Report numbers: 000146129, 000191438, 000335588, 000335771, 000338151, 000345474, 00389283, 000390319, 000593310, E2B_00570261, E2B_00570262, E2B_00570263, E2B_00570264.Organization: Health Canada
February 2024
Req # A-2020-000388
Adverse Drug Reactions (ADRs). Report numbers: E2B_02731350, E2B_02777680, E2B_02810755, E2B_02838946, E2B_02852030, E2B_02856401, E2B_02777244, 000735201, E2B_02869967, E2B_02869987, E2B_02869946, E2B_02871897, E2B_02871900, E2B_02871882, E2B_02871883.Organization: Health Canada
February 2024
Req # A-2020-000647
Adverse Drug Reactions (ADRs) for PANTOPRAZOLE. Report numbers: 000736259, 000738096, 000911912, E2B_02993730, E2B_03001785, E2B_03004317, E2B_03005410, E2B_03015111, E2B_03020794, E2B_03024205, E2B_03034122, E2B_03038830, E2B_03047792. ADRs for PANTOPRAZOLE MAGNESIUM. Report numbers: E2B_03047105, E2B_03003181, E2B_03005697, 000908663. ADR for PANTOPRAZOLE SODIUM. Report number: E2B_03045008. ADR for TECTA. Report number: E2B_03014229.Organization: Health Canada
February 2024
Req # A-2020-000731
Adverse Drug Reactions (ADRs) for Estrogel. Report numbers: 000693076, E2B_002778333. ADR for Ezetrol. Report number: E2B_01181304. ADRs for Fosamax. Report numbers: 000675450, 00685185, E2B_00037382, 000518360, 000555402, 000543195, E2B_00256053, E2B_00066044.Organization: Health Canada
February 2024
Req # A-2020-000800
Adverse Drug Reactions (ADRs) for Fosamax. Report numbers: E2B_00498826, E2B_00498902, E2B_00500827, E2B_00506460, E2B_00786970, E2B_00894613, E2B_00894617, E2B_00894629, E2B_00896465, E2B_00898784, E2B_00898796, E2B_00898918, E2B_00941125, E2B_00944258, E2B_00946463, E2B_00947254, E2B_00786948, E2B_00792724, E2B_01103249, E2B_01104135.Organization: Health Canada
February 2024
Req # A-2020-000870
Adverse Drug Reactions (ADRs). Report numbers: E2B_01674763, E2B_02137119, 000723810, 000724215, 000724308, 000724654, 000724751, E2B_02429833, E2B_02438547, E2B_02304224, E2B_02304226, E2B_02359312.Organization: Health Canada
February 2024
Req # A-2020-001098
Adverse Drug Reactions (ADRs). Report numbers: E2B_02122343, E2B_02124829, E2B_02125454, E2B_02124823, E2B_02198090, E2B_02174028, E2B_02198927, E2B_02251024, E2B_02262610, E2B_02268152,E2B_02236011, E2B_02302657, E2B_02312268, E2B_02272665, E2B_02296322, E2B_02304916, E2B_02296326, E2B_02296362, E2B_02297747, E2B_02427141.Organization: Health Canada
February 2024
Req # A-2020-001185
Adverse Drug Reactions (ADRs). Report numbers: E2B_02432721, E2B_02432728, E2B_02432900, E2B_02432947, E2B_02433003, E2B_02433242, E2B_02433328, E2B_02433386, E2B_02434051, E2B_02434786, E2B_02435446, E2B_02435609, E2B_02435740, E2B_02436225, E2B_02436576, E2B_02436758, E2B_02437312, E2B_02437339, E2B_02437343.Organization: Health Canada
February 2024
Req # A-2020-001227
Adverse Drug Reactions (ADRs). Report numbers: E2B_02538249, E2B_02538715, E2B_02538723, E2B_02539929, E2B_02539930, E2B_02540245, E2B_02541195, E2B_02541203, E2B_02541612, E2B_02541907, E2B_02542078, E2B_02543068, E2B_02543070, E2B_02543071, E2B_02543073, E2B_02543087, E2B_02543655, E2B_02544120, E2B_02544258, E2B_02545002.Organization: Health Canada
February 2024